Palvella Therapeutics (PVLA) Profit After Tax (QoQ) (2013 - 2026)

Palvella Therapeutics (PVLA) Profit After Tax (QoQ) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Palvella Therapeutics 1.88 Bn 1.61 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -23.81%
Dec 31, 2025 -12.25%
Sep 30, 2025 -19.79%
Jun 30, 2025 -15.50%
Mar 31, 2025 -107.54%
Dec 31, 2024 43.31%
Sep 30, 2024 -67.04%
Jun 30, 2024 -64.51%
Mar 31, 2024 -106.68%
Dec 31, 2023 451.47%
Sep 30, 2023 -370.00%
Jun 30, 2023 130.34%
Mar 31, 2023 -68.58%
Dec 31, 2022 19.68%
Sep 30, 2022 5.48%
Jun 30, 2022 -101.92%
Mar 31, 2022 39.37%
Dec 31, 2021 49.01%
Sep 30, 2021 -6.45%
Jun 30, 2021 -320.85%